{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:42Z","timestamp":1786986882141,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.clinthera.2014.03.015","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T12:00:16Z","timestamp":1398772816000},"page":"940-952","source":"Crossref","is-referenced-by-count":7,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Parathyroid Hormone (1\u201334) in Healthy Chinese Subjects"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"chictr-onc-12002874","registry":"10.18810\/chictr"}],"author":[{"given":"Yani","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fandian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.03.015_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2014.03.015_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jbmr.519","article-title":"Rapidly increasing rates of hip fracture in Beijing, China","volume":"27","author":"Xia","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2014.03.015_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5312\/wjo.v2.i8.67","article-title":"Datta. Osteoporotic fracture and parathyroid hormone","volume":"2","author":"Nabanita","year":"2011","journal-title":"World J Orthop"},{"key":"10.1016\/j.clinthera.2014.03.015_bib4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00198-009-0925-y","article-title":"Osteoporosis in China","volume":"20","author":"Wang","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2014.03.015_bib5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ncpendmet0941","article-title":"Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis","volume":"4","author":"Papapoulos","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2014.03.015_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ecl.2012.04.005","article-title":"Combination\u00a0anabolic\u00a0and\u00a0antiresorptive\u00a0therapy for osteoporosis","volume":"41","author":"Cusano","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.clinthera.2014.03.015_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11926-009-0023-3","article-title":"Clinical\u00a0update\u00a0on\u00a0teriparatide","volume":"11","author":"File","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clinthera.2014.03.015_bib8","first-page":"343","article-title":"Teriparatide: indications\u00a0beyond\u00a0osteoporosis","volume":"16","author":"Cheng","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2014.03.015_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrendo.2011.146","article-title":"Antiresorptive\u00a0therapies for osteoporosis: a clinical overview","volume":"8","author":"Chen","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clinthera.2014.03.015_bib10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect\u00a0of\u00a0parathyroid hormone\u00a0(1\u201334) on\u00a0fractures\u00a0and\u00a0bone mineral density in\u00a0postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.03.015_bib11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1185\/03007990902790993","article-title":"Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment","volume":"25","author":"Prevrhal","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.03.015_bib12","first-page":"18","article-title":"The\u00a0skeletal\u00a0response\u00a0to\u00a0teriparatide is largely independent\u00a0of\u00a0age, initial\u00a0bone\u00a0mineral\u00a0density, and\u00a0prevalent vertebral fractures in\u00a0postmenopausal\u00a0women\u00a0with\u00a0osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J\u00a0Bone\u00a0Miner Res"},{"key":"10.1016\/j.clinthera.2014.03.015_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/jc.2009-0358","article-title":"Effect\u00a0of transdermal\u00a0teriparatide administration\u00a0on bone mineral density\u00a0in postmenopausal\u00a0women","volume":"95","author":"Cosman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2014.03.015_bib14","first-page":"418","article-title":"Efficacy of teriparatide in\u00a0increasing bone mineral density in postmenopausal women with osteoporosis-an Indian experience","volume":"56","author":"Sethi","year":"2008","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.clinthera.2014.03.015_bib15","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2014.03.015_bib16","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.03.015_bib17","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2014.03.015_bib18","first-page":"149","article-title":"Effects\u00a0of\u00a0teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J\u00a0Bone\u00a0Miner Res"},{"key":"10.1016\/j.clinthera.2014.03.015_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00198-010-1222-5","article-title":"Adrenal\u00a0effects\u00a0of\u00a0teriparatide in the\u00a0treatment\u00a0of\u00a0severe postmenopausal\u00a0osteoporosis","volume":"22","author":"Lasco","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2014.03.015_bib20","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2014.03.015_bib21","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1007\/s00198-012-1955-4","article-title":"Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis","volume":"23","author":"Michalska","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2014.03.015_bib22","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/jps.20720","article-title":"Pharmacokinetics and hepatic extraction of recombinant human parathyroid hormone, hPTH (1\u201334), in rat, dog, and monkey","volume":"95","author":"Jones","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2014.03.015_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijpharm.2006.03.005","article-title":"Recombinant human parathyroid hormone 1\u201334: pharmacokinetics, tissue distribution and excretion in rats","volume":"317","author":"Hu","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2014.03.015_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/00498254.2011.622811","article-title":"The role of the liver and kidneys in the\u00a0pharmacokinetics of subcutaneously administered teriparatid eacetate\u00a0in rats","volume":"42","author":"Serada","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2014.03.015_bib25","first-page":"869","article-title":"Pharmacokinetics\u00a0and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers","volume":"62","author":"Chu","year":"2007","journal-title":"Pharmazie"},{"key":"10.1016\/j.clinthera.2014.03.015_bib26","series-title":"Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (49348\/2005)","year":"2006"},{"key":"10.1016\/j.clinthera.2014.03.015_bib27","unstructured":"World Medical Association Declaration of Helsinki-ethical principles for medical research involving human subjects. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html. Accessed May 4, 2013."},{"key":"10.1016\/j.clinthera.2014.03.015_bib28","unstructured":"European Medicine Agency. ICH Topic E 6 (R1): Guideline for Good Clinical practice. http:\/\/www.emea.europa.eu\/pdfs\/human\/ich\/013595en.pdf. Accessed May 4, 2013."},{"key":"10.1016\/j.clinthera.2014.03.015_bib29","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioanalytical method validation. May 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf. Accessed May 4, 2013."},{"key":"10.1016\/j.clinthera.2014.03.015_bib30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2217\/17455057.2.3.447","article-title":"Parathyroid hormone\u00a0(1\u201384) and teriparatide\u00a0in the\u00a0treatment of\u00a0postmenopausal osteoporosis","volume":"2","author":"Bogado","year":"2006","journal-title":"Womens Health (Lond Engl)"},{"key":"10.1016\/j.clinthera.2014.03.015_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1742-7843.2011.00768.x","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers","volume":"110","author":"Liu","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2014.03.015_bib32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2146\/ajhp070171","article-title":"Teriparatide in the treatment of osteoporosis","volume":"65","author":"Stroup","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2014.03.015_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1359\/JBMR.051023","article-title":"Teriparatide [human PTH(1\u201334)]: 2.5 years of experience on the use and safety\u00a0of the\u00a0drug\u00a0for the\u00a0treatment of\u00a0osteoporosis","volume":"21","author":"Tashjian","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2014.03.015_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00198-012-2159-7","article-title":"Effects\u00a0of a\u00a0single\u00a0injection\u00a0of\u00a0teriparatide on\u00a0bone\u00a0turnover\u00a0markers in\u00a0postmenopausal\u00a0women","volume":"24","author":"Shiraki","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2014.03.015_bib35","unstructured":"Forteo (teriparatide) [package insert]. Indianapolis, IN: Eli Lilly and Co; 2004."},{"key":"10.1016\/j.clinthera.2014.03.015_bib36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1345\/aph.1D353","article-title":"Teriparatide for severe\u00a0osteoporosis","volume":"38","author":"Cappuzzo","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2014.03.015_bib37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics\u00a0of\u00a0teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2014.03.015_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0009-9236(97)90169-7","article-title":"Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers","volume":"61","author":"Schwietert","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2014.03.015_bib39","first-page":"1535","article-title":"Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1\u201334): kinetics and biochemical response in estrogenized osteoporotic patients","volume":"77","author":"Lindsay","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2014.03.015_bib40","first-page":"60","article-title":"Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1\u201334) [PTH-(1\u201334)] and PTH-related peptide-(1\u201334) in healthy young humans","volume":"80","author":"Fraher","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2014.03.015_bib41","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.2165\/0003495-200868180-00012","article-title":"Teriparatide: a review of its use in osteoporosis","volume":"68","author":"Blick","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2014.03.015_bib42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00774-011-0314-4","article-title":"Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy","volume":"30","author":"Tsujimoto","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.clinthera.2014.03.015_bib43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1507\/endocrj.K07E-123","article-title":"Endogenous intact PTH is suppressed during teriparatide (rhPTH 1\u201334) administration in postmenopausal women with established osteoporosis","volume":"55","author":"Anastasilakis","year":"2008","journal-title":"Endocr J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T10:57:35Z","timestamp":1538650655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0149291814001830"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.03.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}